TY - JOUR
T1 - Role of baseline pol genotype in HIV-1 fitness evolution
AU - Weber, Jan
AU - Rangel, Hector R.
AU - Chakraborty, Bikram
AU - Marotta, Michael L.
AU - Valdez, Hernan
AU - Fransen, Katrien
AU - Florence, Eric
AU - Connick, Elizabeth
AU - Smith, Kimberly Y.
AU - Colebunders, Robert L.
AU - Landay, Alan
AU - Kuritzkes, Daniel R.
AU - Lederman, Michael M.
AU - Vanham, Guido
AU - Quiñones-Mateu, Miguel E.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Viral fitness can be modified upon development of antiretroviral drug resistance, usually by selection of compensatory mutations. In this study, we have used HIV-1 isolates from individuals receiving a protease inhibitor (PI)-based regimen to analyze the impact of basal genetic background on viral fitness evolution. Paired plasma samples and HIV-1 isolates were obtained from 10 PI-naive HIV-infected individuals enrolled in 2 different studies of combination antiretroviral therapy. Genomic regions from pol and env were sequenced. Viral fitness was measured using growth competition experiments followed by heteroduplex tracking analysis. Baseline genotypic analyses of pol showed that 9 of 10 viruses had a different degree of secondary mutations in the protease gene at codons associated with PI resistance (i.e., 10I, 36I, 63P, 71T, and 77I). After 48 weeks of PI-based therapy, a strong correlation was observed between protease genetic divergence and viral fitness difference (r = 0.78, P = 0.03), but not with reverse transcription or Env divergence, suggesting that genotypic changes in the protease gene were driving HIV-1 evolution in these patients. As expected, an inverse correlation was observed between the number of protease and reverse transcription primary mutations and viral fitness (r = -0.65, P < 0.0001). However, our results suggest that the preexistence of secondary mutations in protease genetic background may have implications in HIV-1 fitness evolution and virologic response to antiretroviral therapy.
AB - Viral fitness can be modified upon development of antiretroviral drug resistance, usually by selection of compensatory mutations. In this study, we have used HIV-1 isolates from individuals receiving a protease inhibitor (PI)-based regimen to analyze the impact of basal genetic background on viral fitness evolution. Paired plasma samples and HIV-1 isolates were obtained from 10 PI-naive HIV-infected individuals enrolled in 2 different studies of combination antiretroviral therapy. Genomic regions from pol and env were sequenced. Viral fitness was measured using growth competition experiments followed by heteroduplex tracking analysis. Baseline genotypic analyses of pol showed that 9 of 10 viruses had a different degree of secondary mutations in the protease gene at codons associated with PI resistance (i.e., 10I, 36I, 63P, 71T, and 77I). After 48 weeks of PI-based therapy, a strong correlation was observed between protease genetic divergence and viral fitness difference (r = 0.78, P = 0.03), but not with reverse transcription or Env divergence, suggesting that genotypic changes in the protease gene were driving HIV-1 evolution in these patients. As expected, an inverse correlation was observed between the number of protease and reverse transcription primary mutations and viral fitness (r = -0.65, P < 0.0001). However, our results suggest that the preexistence of secondary mutations in protease genetic background may have implications in HIV-1 fitness evolution and virologic response to antiretroviral therapy.
KW - Protease
KW - Secondary mutations
KW - Viral fitness
UR - http://www.scopus.com/inward/record.url?scp=0042816457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042816457&partnerID=8YFLogxK
U2 - 10.1097/00126334-200308010-00005
DO - 10.1097/00126334-200308010-00005
M3 - Article
C2 - 12869833
AN - SCOPUS:0042816457
SN - 1525-4135
VL - 33
SP - 448
EP - 460
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 4
ER -